## **Supplementary Table 1:** Summary of studies investigating the role of the gut microbiome in ICI therapy

ICI Therapy	Tumour	Model	Relevant Intestinal Microbes in Responders	Relevant Intestinal Microbes in Non- Responders	Relevant Intestinal Microbes: Side effects	Publication Author, Year and Reference
Anti-PD-L1 mAbs	Melanoma	Mouse	Bifidobacterium breve, Bifidobacterium longum			Sivan, 2015 PMID: 26541606
Anti-CTLA-4 mAbs (ipilimumab)	Melanoma, MM, NSCLC	Mouse	Bacteroides thetaiotamicron, Bacteroides fragilis, Burkholderiales		Reduced Colitis: Bacteroides fragilis, Burkholderia cepacia	Vétizou, 2015 [77]
Anti-CTLA-4 mAbs (ipilimumab) and/or anti-PD-1 (nivolumab) mAbs	Melanoma	Human	Firmiticutes phylum: Ruminococcus and Lachnospiraceae genus (relatives of Faecalibacterium prausnitzii L2-6, Gemmiger formicilis, butyrate-producing bacterium L2-21)	Bacteroides	Induced Colitis: Firmicutes (Faecalibacterium prausnitzii, Gemminger formicilis) Reduced colitis: Bacteroidetes	Chaput, 2017 PMID: 28368458
Anti-CTLA-4 mAbs (ipilimumab) and/or anti-PD-1 (nivolumab or pembrolizumab) mAbs	Melanoma	Human	Faecalibacterium prausnitzii, Bacteroides thetaiotamicron, Holdemania filiformis, Dorea formicogenerans, Bacteroides caccae			Frankel, 2017 [76]
Anti-PD-1 or anti-PD-L1 mAbs	NSCLC, renal cell carcinoma, urothelial carcinoma	Human/mouse	Akkermansia muciniphilia, Alistipes indistinctus			Routy, 2018 [75]
Anti-PD-1 or anti-CTLA-4 mAbs	Melanoma	Human/mouse	Enterococcus faecium, Collinsella aerofaciens, Bifidobacterium adolescentis, Klebsiella pneumoniae, Veillonella parvula, Parabacteroides merdae, Lactobacillus sp., Bifidobacterium longum	Ruminococcus obeum, Roseburia intestinalis		Matson, 2018 PMID: 29302014
Anti-PD-1 (pembrolizumab) mAbs	Melanoma	Human/mouse	Ruminococcaceae	Bacteriodales		Gopalakrishnan, 2018 PMID: 29097493